For years, scientists have said that aspirin has the potential to protect people from the deadly grip of colorectal cancer. But only now are they unlocking just how this common pain reliever may pull off such a feat. Further lab analysis showed aspirin exposure increased the expression of the CD80 protein on certain immune cells.
CD80 is known for regulating cell activity, and its increased expression enhanced the immune cells’ ability to detect tumor-associated proteins. Rectal cancer patients using aspirin exhibited higher CD80 levels in healthy rectal tissue, suggesting aspirin stimulated increased immune surveillance. “Our study shows a complementary mechanism of cancer prevention or therapy with aspirin besides its classical drug mechanism involving inhibition of inflammation,” Dr.
Marco Scarpa, a general surgeon at the University of Padova Hospital in Italy and the study’s principal investigator, said in a press release. Aspirin may also protect against colorectal cancer by reducing inflammation, which can impair the immune system’s ability to fight cancer, Nazlie Latefi, who holds a doctorate in neuroscience, biochemistry, and molecular biology and is not associated with the study, told The Epoch Times. Evidence shows this naturally occurring substance is proving effective against significant health threats.
Despite the benefits, all medications, including aspirin, carry potential risks. Though typically safe, aspirin can cause gastrointestinal ulcers, increa.
